Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Valneva Wins DoD Contract for IXIARO | Contract Pharma

What are you searching for?

Sign in
Breaking News

Valneva Wins DoD Contract for IXIARO

Will supply Japanese encephalitis vaccine IXIARO under a new contract lasting up to three years.

By: Contract Pharma

Contract Pharma Staff

Valneva SE, a specialty vaccine company, has signed a new contract, lasting up to three years, with the U.S. government Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine IXIARO.

The new contract, one base year, plus two option years, has a base-year value of $61 million. The DoD has the option to purchase a total of $76 million – $105 million worth of IXIARO across the two option years.  Deliveries for the base-year will begin 4Q20.

Franck Grimaud, Chief Business Officer of Valneva commented, “We are very pleased with this new contract including the longer duration of up to three years – a clear demonstration of the clinical need for personnel deployed to JE endemic areas. The U.S. military has been using IXIARO® for the past ten years and we are excited to continue to help protect military personnel, their families, civilian government service personnel, and government contractors from this potentially deadly disease.”

IXIARO is the only JE vaccine approved by the U.S. FDA, having been developed through a cooperative research and development agreement with the Walter Reed Army Institute of Research. Valneva markets and distributes IXIARO directly to the U.S. military and U.S. private market.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics